Overview of Cefradine

Quick Facts: Cefradine Identity

Property	Description
Active ingredient	Cefradine (Cephradine)
Form	Capsules, Oral Suspension, Sterile Powder/Liquid
Pharmacological class	First-Generation Cephalosporin, beta-Lactam Antibiotic
General purpose	Fighting susceptible bacterial infections
Origin	Semi-synthetic

What is Cefradine and What Type of Antibiotic is It?

Cefradine, often referred to as Cephradine, is a potent semi-synthetic beta-lactam antibiotic belonging to the first-generation cephalosporin group. This drug is chemically synthesized from a natural core structure, which defines it as a semi-synthetic substance. Its classification is firmly established based on the inclusion of the beta-lactam ring, a characteristic feature that dictates its therapeutic action. It is clinically recognized as an effective first-generation agent, primarily known for its reliable activity against susceptible Gram-positive bacteria. Common trade names for this formulation include Anspor and Velosef.

Understanding the General Purpose of Cefradine

The general purpose of Cefradine is to eliminate harmful bacterial infections by acting as a strong bactericidal agent. This means the drug is engineered to directly kill the invading microorganisms. It achieves this by disrupting the final stage of the bacteria's process to build and maintain their cell wall, leading to the collapse and death of the bacterial cell. As a single-ingredient product, it is used to target a wide scope of susceptible bacteria that cause common ailments. The widespread clinical use of this class of antibiotics underscores its medical importance.

What Forms and Route of Administration Does Cefradine Have?

Cefradine is a versatile product available in several high-level pharmaceutical forms to suit various patient needs. It is commonly prepared for oral administration as capsules and as an oral suspension (liquid). The liquid suspension is crucial for enabling accurate and convenient dosing for the pediatric patient group. Furthermore, it is available in a sterile form for parenteral administration, which is delivered as an injection (intramuscular or intravenous). This flexibility ensures that the appropriate administration method can be used, whether for convenient outpatient therapy or for more critical, supervised care.

Regulatory References

WHO Model List of Essential Medicines

What side effects are possible with Cefradine?

Possible Side Effects and Safety Information

The official safety profile for Cefradine (Cephradine) is established through regulatory classification of adverse reactions and essential safety constraints, derived from authoritative government sources. Adverse reactions are grouped by System-Organ Class (SOC) and documented frequency.

Documented Adverse Reaction Categories

The most frequently observed adverse reactions are categorized within the Gastrointestinal System, including diarrhea, nausea, and vomiting. Reactions affecting the Skin and Subcutaneous Tissue, such as rash and urticaria, are also commonly listed. The safety profile also includes reports of transient elevations of liver enzymes and changes in the Blood and Lymphatic System, such as eosinophilia.

Serious Adverse Reactions and Key Constraints

Official prescribing information flags certain events as serious, including severe hypersensitivity reactions like anaphylaxis, and pseudomembranous colitis, which must be considered in patients who develop significant diarrhea during or after therapy.

Cefradine is contraindicated in individuals with a known hypersensitivity to cephalosporins. Caution is explicitly advised regarding potential cross-allergenicity in patients with a documented penicillin allergy. Furthermore, the drug may lead to false-positive results in certain diagnostic laboratory tests, such as those for urinary glucose.

Population-Specific Safety Notes

The regulatory profile highlights specific safety considerations for patients with renal impairment, where dosage adjustment is required due to the prolonged half-life and primary route of drug excretion. Safety notes also emphasize the risk of superinfection with prolonged use.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents detailing the necessary actions and documented manifestations in the event of an overdose.

Documented Manifestations and Serious Risks

Official labeling characterizes Cefradine overdose primarily by non-specific gastrointestinal disturbances. These can include:

Nausea and Vomiting
Diarrhoea
Epigastric distress or stomach upsets

Of critical concern is the documented risk of seizures or convulsions, a severe outcome associated with very high concentrations of cephalosporins in the system. This risk is notably increased in patients with impaired renal function.

Official Emergency Actions Required

In the event of suspected Cefradine overdose, the regulatory guidance is to seek emergency medical attention immediately.

No specific antidote for Cefradine is documented in official prescribing information. Management is supportive and procedural:

Supportive Treatment: Treatment is mainly symptomatic and aimed at maintaining vital functions.
Decontamination: Procedures like gastric lavage may be necessary if a large amount of the drug has been recently ingested.
Monitoring: Severe overdosage requires close hospital monitoring, including laboratory checks of renal function, hepatic function, and coagulation status.
Dialysis: The drug is dialyzable, and haemodialysis may be utilized to help remove the drug from the body in cases of severe toxicity.

Therapeutic Uses of Cefradine

The primary therapeutic role of Cefradine is providing support for managing conditions that are associated with acute or disruptive bacterial episodes. As a first-generation cephalosporin, it is applied across several therapeutic domains to help ease the overall symptom burden caused by susceptible infections. This class of medication is commonly used for infections of the skin, respiratory tract, and urinary system.

Main Uses and Symptom Management

Cefradine is commonly used to help with acute bacterial infections, including those affecting the respiratory system (tonsillitis, bronchitis, pharyngitis, pneumonia), the skin and soft tissues (cellulitis, abscesses, infected wounds), and the genitourinary tract (cystitis, pyelonephritis). It helps address symptom clusters like fever, throat pain, localized redness, swelling, and painful urination (dysuria). The medication may provide supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability. It is also applied in clinical settings for managing certain bone and joint infections and for supportive use during surgical procedures to mitigate the risk of infection.

“Cefradine is relevant in conditions characterized by periods of heightened symptoms, contributing to easing the overall symptom load during symptomatic phases.”

Quick Fact: Supportive Management for Acute Discomfort

Symptom Domain	Supportive Relief	Clinical Context
Systemic & Local Pain	Supports easing the overall symptom burden	Used in community-acquired acute infections
Urinary Distress	Helps manage painful, frequent urination	Relevant in episodic or recurrent UTIs
Respiratory Discomfort	Contributes to easing throat pain and fever	Applied in acute pharyngitis and bronchitis

Regulatory References

Cephalosporins - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cefradine

Official regulatory documents define strict criteria for the use of Cefradine (Cephradine), focusing primarily on patient history, age, and organ function.

Contraindicated Populations

Cefradine must not be used if a patient has a known hypersensitivity or allergy to Cefradine itself or to any other cephalosporin antibiotic. Use is also restricted and requires great caution in individuals with a documented hypersensitivity to penicillin due to the potential for cross-allergenicity.

Condition-Based and Age Restrictions

Category	Regulatory Status
Pediatric Eligibility	Established for children older than age 9 months. Use is not established for infants under this age.
Renal Function	Conditional use required for patients with impaired renal function, necessitating special consideration.
Gastrointestinal History	Use with caution in patients with a history of colitis or certain other intestinal disorders.
Pregnancy	Assigned FDA Pregnancy Category B. Use is permitted only when the need is clearly established.
Lactation	Considered acceptable in nursing mothers but requires caution, as the drug is excreted in small amounts into breast milk.

These constraints ensure that Cefradine is used only in populations where its safety profile has been officially reviewed and established by health authorities.

What should I know about interactions with other medicines?

Cefradine Interactions with other medicines and products

This section outlines the officially documented interaction profile of Cefradine (Cephradine), focusing on how its co-administration with other substances is described in regulatory prescribing information.

Documented Pharmacokinetic and Pharmacodynamic Interactions

The most significant interactions involve the drug’s elimination from the body and the potential for enhanced organ toxicity.

Interacting Substance/Class	Official Interaction Description
Probenecid	Documented to raise the serum concentration of Cefradine by officially reducing its renal clearance through inhibition of tubular secretion.
Aminoglycoside Antibiotics	Co-administration is officially noted for its potential to enhance the risk of nephrotoxicity (kidney toxicity).
Loop Diuretics (e.g., Furosemide)	May officially increase the potential for nephrotoxicity when used concurrently with cephalosporins.

Mechanism of Action

Cefradine is a beta-lactam molecule that acts as an inhibitor of bacterial cell wall synthesis. The primary biological targets are bacterial penicillin-binding proteins (PBPs), which are transpeptidases essential for forming the peptidoglycan layer. The beta-lactam ring structure of Cefradine chemically mimics the D-alanyl-D-alanine terminal end of the peptidoglycan precursor. This allows the drug to covalently acylate the active site serine residue of PBPs. This molecular interaction inactivates the enzyme, specifically inhibiting the transpeptidation and transglycosylation steps of the peptidoglycan synthesis pathway. The resulting disruption prevents the essential cross-linking of linear peptidoglycan strands, yielding a structurally defective and osmotically unstable cell wall. The intracellular consequence is a failure to maintain cell integrity against internal turgor pressure. The downstream cascade involves the activation or removal of inhibition of bacterial autolytic enzymes (autolysins), which further degrade the weakened cell wall. The system-level physiological consequence in the microorganism population is cell lysis and structural disintegration.

Dosage and Administration Information

How to Use Cefradine: Administration Guidelines

Cefradine (also known as Cephradine) is administered according to established guidelines. The formulations dictate the appropriate routes of administration, which include oral (capsule or suspension) and parenteral (Intramuscular [IM] or Intravenous [IV] injection or infusion).

Dosing and Frequency

Patient Population	Standard Dosing Regimen	Frequency
Adults (Oral)	250 mg to 1 g	Every 6 or 12 hours
Adults (Parenteral)	500 mg to 1 g	Every 6 hours
Pediatric	25 to 50 mg/kg/day	Divided into 2 or 4 equal doses

The maximum adult dose may reach 8 g per day for severe infections. Oral forms may be taken with or without food.

Procedural and Safety Requirements

Duration: Treatment must typically continue for a minimum of 48 to 72 hours after the patient is asymptomatic. For infections caused by Streptococcus, treatment must be maintained for at least 10 days.

Administration Specifics:

IV Injection must be administered slowly over a period of 3 to 5 minutes.
IM Injection should be deep into a large muscle mass.
Reconstitution is required for both the oral suspension and the powder for injection, following specific dilution instructions before administration.

Special Instructions: Dosage must be adjusted and reduced in patients with impaired renal function based on their Creatinine Clearance levels. Cefradine must not be administered intrathecally.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefradine

Respiratory Tract Infections (Upper and Lower)

Research has explored the use of Cefradine in managing respiratory tract infections, particularly those characterized by fluctuating or episodic manifestations in the throat, sinuses, and lungs. Early studies focused on how the medication was studied for its potential against susceptible bacteria often associated with these infections. These trials often involved research exploring short-term symptom changes.

Findings describe patterns observed in the studies where changes were measured in patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. For conditions like bacterial pneumonia or bronchitis, the data show patterns related to the evolution of acute episodes. Despite these findings, evidence is limited regarding the use of Cefradine in contemporary settings for certain complex or recurrent conditions. Some older studies have modest sample sizes, and long-term effects are not fully established.

Urinary Tract Infections (UTIs)

Cefradine was evaluated in research involving conditions of the urinary tract, ranging from acute bladder issues (cystitis) to more complex kidney infections (pyelonephritis). Research examined its effect on outcomes related to systemic or functional imbalance caused by bacteria like E. coli.

Clinical findings indicate that Cefradine was associated with patterns of change in susceptible organisms. For example, one study focusing on recurrent infections was observed where measured outcomes were similar to a comparator drug. However, evidence quality varies across studies, and certainty remains low when applying findings from decades-old research. While these studies help contextualize how patients reported their experience, data for certain groups remain insufficient.

Skin and Soft Tissue Infections

Studies have explored the use of Cefradine in managing conditions where symptoms may vary in intensity in the skin and underlying tissues, such as cellulitis and abscesses. Evidence suggests that Cefradine was studied for the common susceptible bacteria, and studies report how symptoms evolved in the observed populations, showing patterns of reduced outcomes linked to inflammatory or irritative states. The research provides insight into short-term changes, but it is important to understand that the results apply only to the populations studied in those specific clinical trials. Subgroup findings are uncertain when considering patients with weakened immune systems.

Use in Surgical Settings (Prophylaxis)

Cefradine was evaluated in research scenarios to explore the chance of infection during and immediately following surgery. This research focuses on observing responses over defined time intervals. The available evidence describes research that explored patterns of infection incidence following the administration of Cefradine at the time of potential contamination. This finding contributes to the broader evidence landscape of preventative measures in surgery. However, follow-up durations were limited to the immediate postoperative period. This type of research provides context but not individual predictions, as many patient and procedural factors can influence the observed outcome.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cefradine (FAQ)

Q: Is Cefradine similar to Cefalexin?

Both Cefradine and Cefalexin are chemically classified as first-generation cephalosporin antibiotics. This pharmacological classification, based on official information, indicates they belong to the same group of β-lactam drugs. They are sometimes utilized for similar types of susceptible bacterial infections.

Q: Can Cefradine affect the results of any lab tests?

Official safety information indicates that Cefradine may lead to false-positive results in certain diagnostic laboratory tests. Specifically, this can occur with certain tests for urinary glucose and the direct Coombs test. Regulatory notes highlight the importance of informing laboratory staff that Cefradine is being taken prior to testing.

Q: How long after the last dose of Cefradine does the drug stay in my system?

Pharmacokinetic data from regulatory documents indicate that Cefradine has a relatively short elimination half-life of approximately 0.5 to 1.5 hours in people with normal kidney function. This means that half of the drug is cleared from the bloodstream within that timeframe. The drug is primarily eliminated from the body unchanged through the urine.

Q: What is the main difference between Cefradine and Penicillin?

Cefradine is classified as a cephalosporin antibiotic, a separate group from penicillin antibiotics. Official labeling notes that caution is necessary because there is a potential for cross-allergenicity—a sensitivity reaction to one drug potentially causing a reaction to the other—between the two drug classes.

Q: Is Cefradine considered a broad-spectrum antibiotic?

Regulatory classification defines Cefradine as a first-generation cephalosporin. This class is primarily known for reliable activity against susceptible Gram-positive bacteria. This classification informs its scope of use, and it is not typically described as a broad-spectrum agent.

Q: Can Cefradine interact with birth control pills?

Official prescribing information states that Cefradine, in common with other antibiotics, might affect the gut flora. This change could potentially lead to lower estrogen reabsorption, and official information suggests a potential for reduced effectiveness of combined oral contraceptives.

Q: Can Cefradine be used by people who have kidney problems?

Official guidelines describe that Cefradine use in patients with impaired renal function (kidney problems) requires careful monitoring. Due to the drug’s elimination route, a modified dosage schedule is specifically mandated based on the degree of reduced kidney function.

Q: What is the risk of developing a yeast infection after taking Cefradine?

The use of an antibiotic like Cefradine carries the general risk of superinfection due to the alteration of the body’s normal bacterial flora. Safety information notes possible vaginal itching or discharge as an adverse reaction, which may relate to fungal or yeast overgrowth.

Q: Does Cefradine have an impact on the liver?

Official adverse reaction reports include the reporting of transient elevations of liver enzymes, which are categorized as abnormal liver function tests. Regulatory documents generally indicate that dosage adjustment is not typically required specifically for liver failure.

Q: Is there a generic version of Cefradine available?

Cefradine is the official chemical name for the active ingredient, which has been marketed under various brand names (e.g., Velosef, Anspor). Due to its status as a semi-synthetic compound, generic versions of the drug entity are commonly available.

Q: Are there official warnings about taking Cefradine with blood thinners?

Yes, official warnings exist regarding the co-administration of Cefradine with the blood thinner Warfarin. This combination is noted in regulatory warnings for its potential to increase the International Normalized Ratio (INR), a measure of blood clotting time, which may raise the risk of bleeding.

Q: What regulatory warnings are there about Cefradine and pre-existing medical conditions?

Regulatory warnings require special caution for patients with specific pre-existing conditions, including impaired renal function (kidney disease) and a history of colitis or certain other gastrointestinal disorders.

Q: Do official documents mention resistance issues with Cefradine?

Official authoritative literature addresses the issue of antibiotic resistance. Cephalosporins, including Cefradine, have been studied in the context of resistance development, particularly in organisms like Staphylococcus aureus.

Q: Is it possible for Cefradine to worsen a fungal infection?

As an antibacterial drug, the prolonged use of Cefradine carries a risk of superinfection due to the alteration of normal body flora. Superinfections may be caused by organisms that are not bacteria, such as fungal organisms.

Q: Does the form of Cefradine (capsule vs. liquid) change how it works?

The mechanism of action, which is the inhibition of bacterial cell wall synthesis, is intrinsic to the Cefradine molecule itself. The different pharmaceutical forms, such as capsules or liquid suspension, are designed to deliver the same active ingredient and produce the same therapeutic effect.

Q: What happens if Cefradine is used for an infection that is not bacterial?

Cefradine is specifically an antibacterial agent engineered to kill susceptible bacteria. Official guidelines prohibit its use for infections that are known to be caused by non-susceptible organisms, such as viruses, as it would not be effective against them.

How should Cefradine be stored and disposed of?

How to Store and Dispose of Cefradine

Cefradine must be stored under specific conditions to maintain stability, as outlined in official labeling.

Storage Requirements

Capsules and Powder must be stored at controlled room temperature (typically 20 C to 25 C). The product must be kept in a tightly closed container and protected from light and moisture.

Reconstituted Oral Suspension must be stored in a refrigerator (2 C to 8 C) and must not be frozen. The refrigerated suspension must be discarded after 14 days.

Disposal and Safety

Like all medications, Cefradine must be stored out of the reach and sight of children.

Unused or expired Cefradine must not be disposed of by flushing it down a toilet or sink drain. Proper disposal should occur through a government-approved method, such as a drug take-back program.

Cefradine